EXHIBIT B



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DEFINAL HUMBER FILMS DATE FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.			
07/800,549 11/27/91 OSHLACK	В	91-318			
		EXAMMER			
STEINBERG & RASKIN					
1140 AVENUE OF THE AMERICAS	ENUE OF THE AMERICAS				
NEW TORK, NY 10036	1502	2			
	ATE WAILED:	07 100 100			
This is a communication from the examinar in charge of your application. COMMISSIONER OF PATERITS AND TRADEMARKS		04/30/92			
This application has been examined Responsive to communication filed on 11-2 A shortened statutory period for response to this action is set to expire 3 month(s), Failure to respond within the period for response will cause the application to become abandoned.		ys from the date of this letter.			
Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:		•			
1. Notice of References Cited by Examiner PTO-892	int Drawing BTO	0.049			
3. Notice of Art Cited by Applicant, PTO-1449. 5. Information on How to Effect Drawing Changes, PTO-1474.	mal Patent Appli	ication, Form PTO-152.			
Part II SUMMARY OF ACTION					
Of the above, claims					
2. Claims	-	have been cancelled.			
3. Claims		are allowed.			
4. X Claims		are rejected.			
5. Claims		are objected to.			
6. Claims are sub					
7. This application has been filed with informal drawings under 37 C.F.R. 1.85 which are according to the control of the contr	ontoble for	to decide requirement.			
8. Formal drawings are required in response to this Office action.	epracie for exam	ination purposes.			
	-				
 The corrected or substitute drawings have been received on	. Under 37 C.F. O-948).	R. 1.84 these drawings			
10. The proposed additional or substitute sheet(s) of drawings, filed on he examiner. disapproved by the examiner (see explanation).		approved by the			
11. The proposed drawing correction, filed on has been approved.	[] diagramma				
12. Acknowledgment is made of the claim for priority under U.S.C. 119. The certified copy has	— usapprove	co (see explanation).			
been filed in parent application, serial no; filed on;	☐ been receiv	ved Li not been received			
 Since this application appears to be in condition for allowance except for formal matters, p accordance with the practice under Ex parte Quayle, 193 i C.D. 11; 453 O.G. 213. 	rosecution as to	the merits is closed in			
14. Other					

Serial No. 800,549

1502 Art. Undit.

-2-

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 1-17 are rejected under 35 U.S.C. \$ 103 as being unpatentable over Goldie et al. U.S. 4,990,341 in view of Oshlack U.S. 4,861,598.

Goldie et al. teaches a controlled release oral, dosage form of an analgesic, hydromorphone, wherein the active ingredient is in a controlled release matrix. See claim 1. Goldie further teaches peak plasma levels attained between 2.25 and 3.75 hours per claim 4. The reference further teaches dosage ranges which are the same as those of applicants. Conventional matrix forming materials are disclosed in columns 3 and 4. Coating materials are shown at col. 4, lines 37-45. Conventional granulation processes are disclosed in the Examples. Although Goldie does not use oxycodone, both oxycodone and hydromorphone being

Serial No. 800,549

- 3 -

Art Unit 1502

derivatives of natural alkaloids with many structural similarities are considered interchangeable in the matrix compositions.

Oshlack is relied on for teaching matrix composition as those of applicants' wherein the active agent is oxycodone. See Example II. Claim 1.

It would have been obvious to one of ordinary skill in the art to use oxycodone in the Goldie et al. invention. The motivation to do so is suggested by a desirability to provide optimum drug bioavailability by controlled release from a matrix composition.

Claims 1-17 are rejected.

Any inquiry concerning this communication should be directed to James M. Spear at telephone number (703) 308-2351.

P

J. Spear/mbb April 27, 1992 THIOPHANA PAGE SUPERVISORY PITTERS EXAMINED ANT UNIT 152

TO SEPARATE.

						RTMENT OF COMMERCE NO TRADEMARK OFFICE					800549				GROU ∫ &	O O	L L	ATTACHMENT TO PAPER NUMBER		NT	2			
NOTICE OF REFERENCES CITED NOTICE OF REFERENCES CITED																								
											ļ	J.S. PAT						. , -				,		
*			DO	ocu	WE	IT N	ю.		DATE					NAME					LASS	SUB- CLASS		FILING DATE IF		
	Α	4	8	6	1	5	9	8	8-	-89	1	05	h	1 lack			4	124	470					
	В	4		9	0	3	4	İ		-91		Gol		die etali			1	124	42	484		H-89		
	С								-														٠.	
	D					<u> </u>					T													
	Ε		-				1				1													
	F	H	-								+													
	G	-	┢	-		┝	\vdash				\top							+		 				
-	н	┝					H	\vdash			\dashv							+		╁				
	-		╀	-		├	-		ļ		\dashv				-			\dashv		1				
-	-	ŀ	├-	-		H	-				+							\dashv		-		-		
	7	_	<u> </u>	-	_	┞	-		-		-	· · · · · · · · · · · · · · · · · · ·							<u> </u>	-				
	K	L.	<u> </u>	<u> </u>		<u>l_</u>	L	<u></u>	<u> </u>			•										<u> </u>	<u>-</u>	
-		1									FOI	REIGN	PATE	ENT D	OCUM	IENT	S				sue	. 1	PERTI	NENT .
*	_	_	DOCUMENT NO.						DATE	4	cc	TNUC	NTRY NAME				CLASS CLA			58	SHTS. DWG	SPEC.		
	L	L				<u> </u>	l.				\perp				_ _				\perp					
_	M	L	L																					
	N																						<u> </u>	
	o																							
	Р																						,	
	a																							
	•		•		(TI	HE:	RRI	EFEF	RENCE	ES (I	ncludii	ng A	uthor	, Title	e, Da	ite, Pe	ertine	ent P	ages, E	tc.)			
	Γ																	•					•	
	R	┢																						
	Г															,								
	s	┢									•••		•	-										
-	-	┢													-								· · · · · · · · ·	
	т	-																						
-	H	┝															-							
	υ	┝																						
1	AMI	_								- 1	YE	•		T		·					 -			
1	Ja	Cr	VI 1	<u>د</u> رم	:/	N_{i}	<	ρρ	ea!		4-	18-	12											
)	Tames M. Spear 4-18-92 *A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, section 707.05 (a).)																							
H	1						(See	Man	al of	rate	nt Exa	mıni	ng Pro	cedu	re, s	ection	1 /07	.U5 I	(a).)				